GlassScriptPhysician profile
Ajax H Yang
NPI 1932155801
$16,809.06
in general payments reported to CMS, 2019-2025
26 companies · $1,817 in 2025
The $1,817 reported for 2025 was more than what 78% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,999 · 2020: $989 · 2021: $1,188 · 2022: $906 · 2023: $7,162 · 2024: $2,749 · 2025: $1,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,074 · Travel and Lodging: $4,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,074.11 |
| Travel and Lodging | $4,653.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,023.24 | 2020-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $2,593.09 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept Rf Probe, Intracept |
| Medtronic USA, INC. | $1,658.94 | 2019-2020 | |
| Painteq LLC | $981.16 | 2021-2024 | Painteq |
| Spinal Simplicity, LLC | $375.63 | 2024-2025 | Ha Minuteman G3-R |
| Nalu Medical, INC. | $347.15 | 2023-2024 | Nalu Neurostimulation System |
| Mml US, INC. | $311.45 | 2023-2025 | Reactiv8 |
| Forte Bio-Pharma LLC | $286.81 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Spr Therapeutics, INC | $244.11 | 2020-2024 | Sprint Pns System |
| Stratus Medical, LLC | $162.60 | 2023 | Nimbus |
| Medtronic, INC. | $136.01 | 2021-2023 | Synchromedii |
| Pfizer INC. | $121.54 | 2019 | |
| Scilex Pharmaceuticals INC. | $107.42 | 2021-2025 | |
| Foundation Fusion Solutions, LLC | $102.29 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.11 | 2024-2025 | Relistor |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $55.54 | 2022-2024 | Xtampza |
| Saluda Medical Americas, INC. | $50.38 | 2022-2024 | Evoke |
| Ibsa Pharma INC. | $46.93 | 2023-2025 | Tirosint, Licart, Flector |
| Averitas Pharma INC. | $22.67 | 2024 | Qutenza |
| Teva Pharmaceuticals USA, INC. | $21.50 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $20.46 | 2024 | |
| Protega Pharmaceutials INC | $19.49 | 2024 | Roxybond |
| Abbvie INC. | $18.19 | 2022 | |
| Vertos Medical, INC. | $15.09 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.26 | 2023 | Seglentis |
| Stimwave Technologies Incorporated | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajax Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.